3041 Patient Derived Xenografts platform focused on developing effective anticancer agents for KRAS and FRFR1/4. (September 2015) - Molina-Pinelo, S.; Meléndez, R.; Salinas, A.; Suarez, R.; Lopez-Jimenez, C.; Carnero, A.; Paz-Ares, L.; Ferrer, I.